The effects of benzofury (5-APB) on the dopamine transporter and 5-HT2-dependent vasoconstriction in the rat

Progress in Neuro-Psychopharmacology and Biological Psychiatry

Volumn 48, Issue , 2014, Pages 57-63

  Dawson, Patrick ^a   Opacka Juffry, Jolanta ^b   Moffatt, James D ^a   Daniju, Yusuf ^b   Dutta, Neelakshi ^b   Ramsey, John ^a   Davidson, Colin ^a  

^a ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

^b UNIVERSITY OF ROEHAMPTON   (United Kingdom)

Author keywords

5 HT2; Accumbens; Benzofury; Dopamine transporter; Prefrontal cortex; Vasoconstriction

Indexed keywords

3BETA (4 IODOPHENYL) 2BETA TROPANECARBOXYLIC ACID ISOPROPYL ESTER; BENZOFURY; DOPAMINE; DOPAMINE TRANSPORTER; IODINE 125; KETANSERIN; PSYCHOTROPIC AGENT; SEROTONIN; SEROTONIN 2A RECEPTOR; SEROTONIN 2B RECEPTOR; TRITIUM; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; AORTA CONSTRICTION; ARTICLE; BINDING AFFINITY; BRAIN TISSUE; CARDIOTOXICITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOPAMINE UPTAKE; DOPAMINERGIC SYSTEM; HALLUCINATION; IN VITRO STUDY; MALE; NERVE STIMULATION; NONHUMAN; NUCLEUS ACCUMBENS; PHARMACOLOGY; PROTEIN INTERACTION; RAT; RECEPTOR BLOCKING; SEROTONINERGIC SYSTEM;

3,4, METHYLENEDIOXYMETHAMPHETAMINE; 3,4-METHYLENEDIOXYAMPHETAMINE; 5-(2-AMINOPROPYL)BENZOFURAN; 5-APB; 5-HT(2); ACCUMBENS; ACMD; ACSF; ADVISORY COUNCIL ON THE MISUSE OF DRUGS; AREA UNDER THE CURVE; ARTIFICIAL CEREBROSPINAL FLUID; AUC; BENZOFURY; DA; DOPAMINE; DOPAMINE TRANSPORTER; LSD; LYSERGIC ACID DIETHYLAMIDE; MDA; MDMA; PFC; PREFRONTAL CORTEX; REGION OF INTEREST; ROI; VASOCONSTRICTION;

ANIMALS; AORTA; BENZOFURANS; BRAIN; COCAINE; DOPAMINE; DOPAMINE PLASMA MEMBRANE TRANSPORT PROTEINS; DOSE-RESPONSE RELATIONSHIP, DRUG; IODINE ISOTOPES; KETANSERIN; MALE; MUSCLE CONTRACTION; N-METHYL-3,4-METHYLENEDIOXYAMPHETAMINE; PROPYLAMINES; PROTEIN BINDING; RATS; RATS, WISTAR; RECEPTORS, SEROTONIN, 5-HT2; SEROTONIN AGENTS; TRITIUM; VASOCONSTRICTION;

EID: 84885356538     PISSN: 02785846     EISSN: 18784216     Source Type: Journal    
DOI: 10.1016/j.pnpbp.2013.08.013     Document Type: Article

References (46)

1. Abbas A., Roth B.L. Arresting serotonin. Proc Natl Acad Sci 2008, 105:831-832.
2. ACMD report on Benzofury [accessed July 10th 2013]. https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/204808/J_TCDO_report_on_5-6APB_and_NBOMe_compounds.pdf.
3. Baxter G.S., Murphy O.E., Blackburn T.P. Further characterization of 5-hydroxytryytamine receptors (putative 5-HT2B) in rat stomach fundus longitudinal muscle. Br J Pharmacol 1994, 112:323-331.
4. Bhattacharyya S., Schapira A.H., Mikhailidis D.P., Davar J. Drug-induced fibrotic valvular heart disease. Lancet 2009, 374:577-585.
5. 2B receptor antagonist. Br J Pharmacol 1999, 127:1075-1082.
6. Brierley D.I., Davidson C. Harmine augments electrically evoked dopamine efflux in the nucleus accumbens shell. J Psychopharmacol 2013, 27:98-108.
7. Carhart-Harris R.L., King L.A., Nutt D.J. A web-based survey on mephedrone. Drug Alcohol Depend 2011, 118:19-22.
8. Davidson C., Ellinwood E.H., Douglas S.B., Lee T.H. Effect of cocaine, nomifensine, GBR 12909 and WIN 35428 on carbon fiber microelectrode sensitivity for voltammetric recording of dopamine. J Neurosci Methods 2000, 101:75-83.
9. Davidson C., Gow A.J., Lee T.H., Ellinwood E.H. Methamphetamine neurotoxicity: necrotic and apoptotic mechanisms and relevance to human abuse and treatment. Brain Res Rev 2001, 36:1-22.
10. Davidson C., Chauhan N.K., Knight S., Gibson C.L., Young A.M.J. Modelling ischaemia in vitro: effects of temperature and glucose concentration on dopamine release evoked by oxygen and glucose depletion in a mouse brain slice. J Neurosci Methods 2011, 202:165-172.
11. Dawson P., Moffatt J.D. Cardiovascular toxicity of novel psychoactive drugs: lessons from the past. Prog Neuropsychopharmacol Biol Psychiatry 2012, 39:244-252.
12. Di Chiara G., Imperato A. Drugs abused by humans preferentially increase synaptic dopamine concentrations in the mesolimbic system of freely moving rats. Proc Natl Acad Sci 1988, 85:5274-5278.
13. Drugs Forum [accessed July 9th 2013]. http://www.drugs-forum.com/forum/showthread.php?t=154505.
14. Egan C.T., Herrick-Davis K., Miller K., Glennon R.A., Teitler M. Agonist activity of LSD and lisuride at cloned 5HT2A and 5HT2C receptors. Psychopharmacology 1998, 136:409-414.
15. Fowler J.S., Volkow N.D., Wang G.J., Gatley S.J., Logan J. [11]Cocaine: PET studies of cocaine pharmacokinetics, dopamine transporter availability and dopamine transporter occupancy. Nucl Med Biol 2001, 28:561-572.
16. Giros B., Jaber M., Jones S.R., Wightman R.M., Caron M.G. Hyperlocomotion and indifference to cocaine and amphetamine in mice lacking the dopamine transporter. Nature 1996, 379:606-612.
17. Glennon R.A. Do classical hallucinogens act as 5-HT2 agonists or antagonists?. Neuropsychopharmacology 1990, 3:509-517.
18. Halberstadt A.L., Geyer M.A. Multiple receptors contribute to the behavioral effects of indoleamine hallucinogens. Neuropharmacology 2011, 61:364-381.
19. Hutcheson J.D., Setola V., Roth B.L., Merryman W.D. Serotonin receptors and heart valve disease - it was meant 2B. Pharmacol Ther 2011, 132:146-157.
20. Hyland B.I., Reynolds J.N., Hay J., Perk C.G., Miller R. Firing modes of midbrain dopamine cells in the freely moving rat. Neurosciences 2002, 114:475-492.
21. ICDP, International Centre for Drug Policy http://www.sgul.ac.uk/research/projects/icdp.
22. Iversen L., Gibbons S., Treble R., Setola V., Huang X.P., Roth B.L. Neurochemical profiles of some novel psychoactive substances. Eur J Pharmacol 2013, 700:147-151.
23. Kaumann A.J., Levy F.A. 5-Hydroxytryptamine receptors in the human cardiovascular system. Pharmacol Ther 2006, 111:674-706.
24. Koob G.F., Volkov N.D. Neurocircuitry of addiction. Neuropsychopharmacology 2010, 35:217-238.
25. Lee T.H., Balu R., Davidson C., Ellinwood E.H. Differential time-course profiles of dopamine release and uptake changes induced by three dopamine uptake inhibitors. Synapse 2001, 41:301-310.
26. Levi M.S., Divine B., Hanig J.P., Doerge D.R., Vanlandingham M.M., George N.I., et al. A comparison of methylphenidate-, amphetamine-, and methamphetamine-induced hyperthermia and neurotoxicity in male Sprague-Dawley rats during the waking (lights off) cycle. Neurotoxicol Teratol 2012, 34:253-262.
27. Mijnster M.J., Raimundo A.G., Koskuba K., Klop H., Docter G.J., Groenewegen H.J., et al. Regional and cellular distribution of serotonin 5-hydroxytryptamine2a receptor mRNA in the nucleus accumbens, olfactory tubercle, and caudate putamen of the rat. J Comp Neurol 1997, 389:1-11.
28. Monte A.P., Marona-Lewicka D., Cozzi N.V., Nichols D.E. Synthesis and pharmacological examination of benzofuran, indan, and tetralin analogues of 3,4(methylenedioxy)amphetamine. J Med Chem 1993, 36:3700-3706.
29. Nagatomo T., Rashid M., Muntasir H.A., Komiyama T. Functions of 5-HT2A receptor and its antagonists in the cardiovascular system. Pharmacol Ther 2004, 104:59-81.
30. Nichols D.E. Hallucinogens. Pharmacol Therapeut 2004, 101:131-181.
31. Passie T., Halbern J.H., Stichtenoth D.O., Emrich H.K., Hintzen A. The pharmacology of lysergic acid diethylamide: a review. CNS Neurosci Ther 2008, 14:295-314.
32. Paxinos G., Watson C. The rat brain in stereotaxic coordinates 5th Edition 2005, Elsevier Academic Press.
33. Petitti D.B., Sidney S., Quesenberry C., Bernstein A. Stroke and cocaine or amphetamine use. Epidemiology 1998, 9:596-600.
34. Pontieri F.E., Tanda G., Orzi F., Di Chiari G. Effect of nicotine in the nucleus accumbens and similarity to those of addictive drugs. Nature 1996, 382:255-257.
35. Rothman R.B., Baumann M.H. Therapeutic and adverse actions of serotonin transporter substrates. Pharmacol Ther 2002, 95:73-88.
36. Rothman R.B., Baumann M.H., Savage J.E., Rauser L., McBride A., Hufeisen S.J., et al. Evidence for possible involvement of 5-HT2B receptors in the cardiac valvulopathy associated with fenfluramine and other serotonergic medications. Circulation 2000, 102:2836-2841.
37. Sato H., Skelin I., Diksic M. Chronic buspirone treatment decreases 5-HT1B receptor densities and the serotonin transporter but increases the density of 5-HT2A receptors in the bulbectomized rat model of depression: an autoradiographic study. Brain Res 2010, 1345:28-44.
38. Setola V., Hufeisen S.J., Grande-Allen K.J., Vesely I., Glennon R.A., Blough B., et al. 3,4-Methylenedioxymethamphetamine (MDMA, "Ecstasy") induces fenfluramine-like proliferative actions on human cardiac valvular interstitial cells in vitro. Mol Pharmacol 2003, 63:1223-1229.
39. Stanczuk A., Morris N., Gardner E.A., Kavanagh P. Identification of (2-aminopropyl)benzofuran (APB) phenyl ring positional isomers in internet purchased products. Drug Test Anal 2013, 5:270-276.
40. 125I]RTI-121 quantitative autoradiography. Neurochem Int 1998, 32:61-68.
41. Sulzer D., Sonders M.S., Poulsen N.W., Galli A. Mechanisms of neurotransmitter release by amphetamines: a review. Prog Neurobiol 2005, 75:406-433.
42. UK Home Office 04 June 2013. https://www.gov.uk/government/news/nbome-and-benzofury-to-be-banned.
43. Vardakou I., Pistos C., Spiliopoulou C. Drugs for youth via internet and the example of mephedrone. Toxicol Lett 2011, 201:191-195.
44. Villaźon M., Padín J.F., Cadavid M.I., Enquix M.J., Tristán H., Orallo F., et al. Characterization of serotonin receptors in rat isolated aorta. Biol Pharm Bull 2002, 25:584-590.
45. Willuhn I., Wanat M.J., Clark J.J., Phillips P.E. Dopamine signaling in the nucleus accumbens of animals self-administering drugs of abuse. Curr Top Behav Neurosci 2010, 3:29-71.
46. Yorgason J.T., Espana R.A., Jones S.R. Demon voltammetry and analysis software: analysis of cocaine-induced alterations in dopamine signaling using multiple kinetic measures. J Neurosci Methods 2011, 202:158-164.